FDA Rejects Nuplazid Application for Treatment of Alzheimer’s Disease Psychosis
The FDA has rejected an application to approve Nuplazid to treat Alzheimer's disease psychosis.
The FDA has rejected an application to approve Nuplazid to treat Alzheimer's disease psychosis.
A new study links an increased risk of teen psychosis to air pollution exposure.
Some ADHD medications may significantly increase the risk of psychosis for first time users, according to the findings of a new study.